Canada warns on illegal retatrutide sales as US seizures jump

Health officials in Canada issued a public warning on August 18 about unapproved and illegal sales of retatrutide, Eli Lilly's experimental triple-hormone weight-loss drug ^[1]. The warning shows that the gray market for this unapproved medicine has spread beyond the United States, where US Customs and Border Protection has also reported a sharp rise in intercepted shipments of illicit GLP-1 drugs ^[1].

Retatrutide is not approved for sale anywhere in the world. It is still in Phase 3 clinical trials, the last stage of testing before a company can ask regulators for approval ^[1]. In the TRIUMPH-1 trial, patients on retatrutide lost an average of 28.3 percent of their body weight over 80 weeks, a result that has drawn attention because it is higher than the weight loss reported for approved drugs like tirzepatide, sold as Mounjaro and Zepbound ^[1]. Two more late-stage trials, TRIUMPH-2 and TRIUMPH-3, produced results on July 23, 2026, and Eli Lilly has said it plans to file for approval with regulators sometime in the first quarter of 2027 ^[1].

Despite that unfinished testing, retatrutide is already being sold illegally, often through websites or compounding operations that are not authorized to make or sell it. US border agents intercepted more than 690 shipments of illicit GLP-1 drugs during all of fiscal year 2025, but seizures jumped to more than 1,400 shipments in July 2026 alone, according to reporting on the trend ^[1]. Canada's warning on August 18 signals that the same problem is showing up north of the border, not just in the United States ^[1].

Why it matters for patients

Because retatrutide has not been reviewed or approved by the FDA, Health Canada, or any other regulator, there is no official confirmation of its safety, correct dosing, or manufacturing quality outside of clinical trial settings ^[1]. Products sold as retatrutide online or through unauthorized sellers have not gone through the checks that approved drugs like semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) have passed. Buyers cannot be sure what is actually in the vial, at what strength, or whether it was stored and shipped correctly.

The rising seizure numbers suggest that demand for retatrutide is outpacing its availability through legitimate research channels, which only exist inside clinical trials right now ^[1]. That gap between demand and supply is what is fueling the gray market on both sides of the US-Canada border ^[1]. For readers weighing options today, only tirzepatide, semaglutide, and orforglipron (sold as Foundayo) are currently approved in the United States for weight management, and each has gone through the FDA review process that retatrutide has not yet completed ^[1].

What happens next

Eli Lilly has guided toward filing for approval of retatrutide with regulators in the first quarter of 2027, following the TRIUMPH-2 and TRIUMPH-3 trial readouts that were reported on July 23, 2026 ^[1]. Until any approval is granted, retatrutide will remain unavailable through legal pharmacy channels in the United States, Canada, or elsewhere, and any product sold under that name outside of a clinical trial is not authorized ^[1]. It is not yet known from available reporting how enforcement agencies in the US and Canada plan to respond to the rising shipment volumes beyond the public warnings already issued ^[1].